Question special
Lead Moderator

After reading Dr. Algarni's questions and the authors' answers, I wonder if the authors and experts could expand upon the pros and cons of RRCTs - what questions are they best used to answer? Are there questions for which they should not be used? Can we harness registry data for evaluation of new therapies in this manner? How does the use of a registry affect the administrative cost of clinical (randomized) trials?